Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 7/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.40 |
| ▸ | HTR3B | O95264 | 3/20 | 0.40 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27265682 | 0.79 | HTR3E (0.43) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL19036185 | 0.75 | MAPK8 (0.46) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27244322 | 0.74 | DAO (0.41) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29789954 | 0.73 | IKBKB (0.42) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL12074764 | 0.73 | CCNE1 (0.43) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17993465 | 0.69 | HTR3E (0.47) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21917529 | 0.68 | PTAFR (0.37) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27244340 | 0.68 | KDM4E (0.50) | MAPT | |
| SCHEMBL1104796 | 0.67 | ROCK1 (0.46) | MAPK8HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29636632 | 0.67 | MAPK8 (0.41) | MAPK8HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | claimed |
| EP-1791844-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-7-(BUT-2-INYL)-XANTHINES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-06 | — | — | EP | claimed |
| US-20060058323-A1 | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | US | claimed |
| WO-2006027204-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-7-(BUT-2-INYL)-XANTHINES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | WO | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | disclosed |
| EP-2190434-B1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| US-7495003-B2 | 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-24 | — | — | US | disclosed |
| EP-1791844-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-7-(BUT-2-INYL)-XANTHINES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-06 | — | — | EP | disclosed |
| US-20060058323-A1 | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | US | disclosed |
| WO-2006027204-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-7-(BUT-2-INYL)-XANTHINES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058323-A1 | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | MAPK8 1571/4885HTR3E 569/4885HTR3B 671/4885 |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | MAPK8 3721/4885HTR3E 3243/4885HTR3B 2396/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | MAPK8 3026/4885HTR3E 3375/4885HTR3B 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.